Northland Downgrades Esperion (ESPR) to Underperform, PT $1, 'uncertainty surrounding ESPR's receipt of $300MM milestone payments'
Tweet Send to a Friend
(Updated - March 16, 2023 10:37 AM EDT)Northland Capital Markets analyst Carl Byrnes downgraded Esperion Therapeutics (NASDAQ: ESPR) from Market ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
